 Home > Biochemistry News > Biotechnology News > Blockbuster PD-L1 inhibitor is approved by FDA to treat early lung cancer and reduce the risk of recurrence by 34%

Blockbuster PD-L1 inhibitor is approved by FDA to treat early lung cancer and reduce the risk of recurrence by 34%

 Last Update: 2021-11-05
 Source: Internet
 Author: User

Tags

text chemistry pdf

cardiovascular disease treatment

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On October 16, Roche announced that the US FDA has approved its blockbuster PD-L1 inhibitor Tecentriq (atezolizumab) as an adjuvant therapy to treat stage II-IIIA non-small cell lung cancer (NSCLC) after surgery and platinum-containing chemotherapy.

This approval is based on the results of an interim analysis of a phase 3 clinical trial

▲The efficacy of Tecentriq in stage II-IIIA NSCLC patients whose tumors express PD-L1 (picture source: reference [2])

In terms of safety, Tecentriq's safety characteristics are consistent with known characteristics, and no new safety signals have been found

Non-small cell lung cancer accounts for about 80-85% of all lung cancers, and about half of early-stage patients will still experience cancer recurrence after surgery

(The original text has been deleted)

Reference materials:

[1] US FDA approves Roche's Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer.

[2] Roche Analyst Event Tuesday, 08 June 2021.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.